The case for & against
Bull & Bear analysis
Bearish
Starling Oncology, Inc. (NASDAQ: STLN) is a pioneering player in the value-based oncology care sector, emphasizing enhanced outcomes while managing treatment costs. The company has established a competitive position as a physician-led organization providing comprehensive services spanning diagnosis, treatment, and supportive care in oncology. With strong growth projections and an expansive service offering, Starling is well-positioned to capitalize on the rising demand for cancer care solutions amidst an evolving healthcare landscape.
Bull says
- ↑Q2 revenue +34.6% YoY to $161.3M; 2026 guidance raised to $650–670M
- ↑Adjusted EBITDA turned positive at $2M for second straight quarter
- ↑Debt refinanced to 2031 without equity dilution, extending maturities
- ↑Analysts lifted price target to $9, implying 24% annual growth
- ↑Technicals show Strong Buy with positive momentum and moving averages
- ↑High liquidity, ~1% dividend yield, and positive rate sensitivity
Bear says
- ↓Earnings yield at –1.74% and profitability score deeply negative
- ↓Leverage remains elevated post-refinancing, posing debt risk
- ↓Consensus Sell rating and elevated short interest reflect skepticism
- ↓Two GuruFocus warning signs highlight potential operational issues
- ↓Volatility high at ~2.19, implying price instability
- ↓Low institutional ownership and weak size scores suggest limited support